Insights
Search Results
Client Highlights
3.31.26
Wilson Sonsini Advises Crosspoint Capital Partners on TENEX.AI’s $250 Million Series B
On March 31, 2026, TENEX.AI, the AI SOC company transforming security operations, announced a $250 million Series B round of financing led by Crosspoint Capital Partners. Wilson Sonsini Goodrich & Rosati advised Crosspoint on the transaction.
The proceeds from the Series B will accelerate TENEX.AI’s global expansion and significantly scale the human expertise behind its AI-native managed detection and response (MDR) service, expanding the team of defenders and engineers delivering cybersecurity outcomes. The TENEX.AI platform enables AI-driven triage, investigation, hunting, and response to threats in under a minute—with 100 percent alert coverage and human analysts governing every decision and accountable for every outcome.
The Wilson Sonsini team that advised Crosspoint on the financing included:
Corporate
Becki DeGraw
Travis Scheft
Michael Murrietta
Enid Qin
The proceeds from the Series B will accelerate TENEX.AI’s global expansion and significantly scale the human expertise behind its AI-native managed detection and response (MDR) service, expanding the team of defenders and engineers delivering cybersecurity outcomes. The TENEX.AI platform enables AI-driven triage, investigation, hunting, and response to threats in under a minute—with 100 percent alert coverage and human analysts governing every decision and accountable for every outcome.
The Wilson Sonsini team that advised Crosspoint on the financing included:
Corporate
Becki DeGraw
Travis Scheft
Michael Murrietta
Enid Qin
Client Highlights
2.02.26
Wilson Sonsini Advises ALX Oncology on Public Offering
On January 30, 2026, ALX Oncology Holdings Inc., a clinical-stage biotechnology company focusing on novel therapies designed to treat cancer and extend patients’ lives, announced the pricing of an underwritten offering of 76,979,112 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,574,120 shares of common stock in the offering. The gross proceeds of the offering are expected to be approximately $150 million before deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any pre-funded warrants. Wilson Sonsini Goodrich & Rosati advised ALX Oncology on the transaction.
Client Highlights
4.02.25
Wilson Sonsini Advises Edgewise Therapeutics on $200 Million Underwritten Offering
On April 2, 2025, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced the pricing of an underwritten offering of 9,935,419 shares of its common stock at an offering price of $20.13 per share. Edgewise anticipates gross proceeds from the offering to be approximately $200 million, before deducting underwriting discounts and commissions and offering expenses. The closing of the offering is expected to occur on April 3, 2025. Wilson Sonsini Goodrich & Rosati represented Edgewise Therapeutics on the transaction.
Client Highlights
4.23.24
Firm Advises Underwriters in Montrose Environmental’s $128 Million Follow-On Public Offering
On April 22, 2024, Montrose Environmental Group, Inc., an environmental services provider offering measurement and analytical services as well as environmental resiliency & sustainability solutions, completed the underwritten public offering of 3,450,000 shares of its common stock at a price of $37.15 per share, including the full exercise of the greenshoe option. Wilson Sonsini Goodrich & Rosati is advising the underwriters in the transaction.
Client Highlights
10.10.23
Wilson Sonsini Advises ALX Oncology on $63 Million Public Offering
On October 5, 2023, ALX Oncology Holdings Inc., an immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system, announced the pricing of its underwritten public offering of common stock and pre-funded warrants. ALX Oncology sold 8,663,793 shares of common stock, which included 1,293,103 shares of common stock pursuant to the full exercise of the underwriters’ option to purchase additional shares and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,250,000 shares of common stock in the offering. The shares of common stock were sold at a public offering price of $6.38 per share and the pre-funded warrants were sold at a public offering price of $6.379 per pre-funded warrant.